您的当前位置:首页 > Knowledge > 【aspect of the embalmer diablo 4】Aptose to Hold Corporate Update Sunday, December 6th 正文
时间:2024-09-29 12:28:57 来源:网络整理 编辑:Knowledge
Corporate event to provideclinicalupdate forCG-806in AML and B-cell CancersPoster Presentations for aspect of the embalmer diablo 4
Corporate event to provide
clinical
update for
CG-806
in AML and B-cell Cancers
Poster Presentations for CG-806 and APTO-253 are scheduled for December
5
th
and
6
th
at 2020 ASH Annual Meeting and Exposition
SAN DIEGO and TORONTO,aspect of the embalmer diablo 4 Dec. 01, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Sunday, December 6
th
, at 2:00 PM PT, in conjunction with participation at the 2020 ASH Annual Meeting. The event will include the current clinical status of CG-806, Aptose’s oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies, as well as a review of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).
Aptose Corporate Update Details
Date
&
Time:
Sunday, December 6, 2020, 2:00 PM PT
Participant Webcast Link
:
http://public.viavid.com/index.php?id=142523
Participant Dial-in:
Toll Free:
Toll/International
:
Conference ID:
1-877-407-9039
1-201-689-8470
13713479
The slides will be available on Aptose’s website
here
and a recording of the presentation will be archived shortly after the conclusion of the event.
As announced previously, early clinical data, along with certain preclinical data for CG-806 and APTO-253, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually Saturday, December 5 – Monday, December 7, 2020. The posters will be available on the presentations page of Aptose website
here
.
Poster Presentation Details
Abstract #1042:
A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
Poster Session D
ate & Time:
Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT
Session Name:
616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Abstract #1174
:
Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
Poster Session
Date & Time:
Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT
Session Name:
625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
Abstract #2228
:
A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin’s Lymphomas
Poster Session
Date & Time:
Sunday, December 6, 2020, 7:00 AM - 3:30 PM PT
Session Name:
642. CLL: Therapy, excluding Transplantation: Poster II
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).
For further information, please contact:
Aptose Biosciences Inc.
Greg Chow
Executive Vice President, CFO
858-926-2730
SMP Communications
Susan Pietropaolo
201-923-2049
LifeSci Advisors, LLC
Dan Ferry, Managing Director
617-430-7576
View comments
Chromadex Corp. to Host Earnings Call2024-09-29 12:01
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Astra Space, Inc. with Losses of $100,000 to Contact the Firm2024-09-29 11:40
6 Things Employees Should Know About the Family and Medical Leave Act2024-09-29 11:39
For France's Macron, 2020 again brings rocky start, outlook2024-09-29 11:21
UPDATE 1-MSCI to quadruple weighting of China A-shares in its global benchmarks2024-09-29 10:48
Merkel: We'll use 6-month withdrawal period to talk if U.S. quits INF treaty2024-09-29 10:24
K&L Gates, Withers Seal Singapore Mergers2024-09-29 10:09
Social Security Schedule: When the First COLA Checks Will Arrive in January 20222024-09-29 10:09
HealthEquity (HQY) Lags Q1 Earnings and Revenue Estimates2024-09-29 10:01
First Circuit Declares Appointment of FOMB Members Violates Appointments Clause2024-09-29 09:58
A Magnificent Ascent For The Newest Cloud ETF2024-09-29 12:25
Trump to meet China's Xi to try to seal trade deal, progress reported2024-09-29 12:14
Higher drug prices ring in the new year for more than 250 pharmaceuticals2024-09-29 12:06
Biden's Treasury nominee Yellen discloses paid speaking gigs for financial firms2024-09-29 11:32
Cheniere seeks U.S. permission to put Oklahoma Midship natgas pipe in service2024-09-29 11:05
Go-Jek Raises $1 Billion From Google, Tencent and Other Internet Giants2024-09-29 11:05
Andrews Sykes Group plc (LON:ASY) Is Employing Capital Very Effectively2024-09-29 10:43
EM ASIA FX-Indonesian rupiah, Thai baht drop; Philippine peso firms2024-09-29 10:17
Green Stream Highlights Recent Video Presenting Company's Unique Solar Energy Solution2024-09-29 10:13
FOMC, NFP, Earnings Headline a Big Week for Global Markets2024-09-29 09:53